Impactful results of the TKI-adjuvant trials in relation to EGFR mutant and ALK-rearranged NSCLC have led to the FDA approvals of osimertinib and alectinib for surgically treated disease and affirmed the need for the genomic testing of patients with NSCLC at all levels of care [57,58]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.